Moderna Inc. said in an update on its mRNA pipeline on Monday that its COVID-19 vaccine sales in 2022 fetched $18.4 billion, with 2023 expected to bring sales of approximately $5 billion from existing contracts, while further contracts are anticipated in the United States, Europe, Japan, and other key markets, APA reports citing Teletrader.
"We enter 2023 in a great position, with significant momentum across our clinical pipeline," CEO Stephane Bancel said. He went on to say that the company's "progress is meeting the high expectations we set out a few years ago, and with encouraging clinical data across the entire Moderna platform, we are accelerating our investments to deliver the greatest possible impact to people through mRNA medicines." The CEO also added that the R&D budget for 2023 is around $4.5 billion.
Follow us on Telegram
t.me/apanewsaz
Follow us on Instagram
Follow us on Facebook
Follow us on Twitter
PHOTO-
